FDA destroys steroid products sold as supplements
ROCKVILLE, Md. The U.S. District Court for the Eastern District of Michigan, Southern Division, on Monday entered a consent decree that condemns and forfeits to the United States for destruction about $1.3 million worth of dietary supplements.
“The court order is the result of efforts by the federal government to protect consumers from products for which there is inadequate information to assure that they do not present a significant or unreasonable risk of illness or injury,” stated Michael Chappell, FDA’s acting associate commissioner for regulatory affairs. “It shows that the agency is prepared to use the necessary legal means to keep such products out of the marketplace.”
At the request of the FDA, U.S. Marshals seized more than 23,300 bottles of three dietary supplement products distributed by LG Sciences of Brighton, Mich. The seized products were marketed for use by body builders and distributed on the Internet and in retail stores under the names “Methyl 1-D,” “Methyl 1-D XL,” and “Formadrol Extreme XL.”
Based on laboratory tests, the FDA determined that the products contain one or more unapproved food additives and/or new dietary ingredients for which there is inadequate information to assure that the ingredients do not present a significant or unreasonable risk of illness or injury. Specifically, the condemned Methyl 1-D and Methyl 1-D XL contained 1,4,6-androstatriene-3,17-dione, also known as “ATD” or 1,4,6-etioallocholan-dione. The condemned Formadrol Extreme XL contained ATD and 3,6,17-androstenetrione (also known as “6-OXO”). Both of these substances are steroids that inhibit the activity of the enzyme aromatase and may be found in dietary supplements promoted to boost testosterone levels.
The FDA has no scientific information concerning the safety of the condemned products or their ingredients and, thus, cannot determine whether they represent a hazard to consumers. Under the circumstances, consumers who use or have used the products should discuss their use with their health care professionals.
The FDA also recommends that consumers consult their health care professionals if they have experienced any adverse events that they suspect are related to the products’ use.
Mosquito gut bacteria may inhibit malaria parasite, researchers say
BALTIMORE, Md. Bacteria in the gut of a mosquito may inhibit infection of Plasmodium falciparum, the parasite that causes malaria in humans, according to researchers at the Johns Hopkins Bloomberg School of Public Health.
Scientists with the Bloomberg School’s Malaria Research Institute found that removing these bacteria, or microbial flora, with antibiotics made the mosquitoes more susceptible to Plasmodium infection because of a lack of immune stimulation. Their study is published in the May 8, edition of the journal PLoS Pathogens.
“Our study suggests that the microbial flora of mosquitoes is stimulating immune activity that protects the mosquito from Plasmodium infection,” stated George Dimopoulos, senior author of the study and associate professor with Johns Hopkins Malaria Research Institute. “The same immune factors that are needed to control the mosquito’s infection from the microbes are also defending against the malaria parasite Plasmodium. … The interplay between bacteria and the mosquito’s immune system may have significant implications for the transmission of malaria in the field where mosquitoes may be exposed to different types of bacteria in different regions. Theoretically, these bacteria could be introduced to the mosquitoes to boost their immunity to the malaria parasite and make them resistant and incapable of spreading the disease. Our current research aims at identifying those bacteria that trigger the strongest mosquito immune defense against the malaria parasite.”
Malaria kills more than one million people worldwide each year; the majority of deaths are among children living in Africa.
Herb works as anti-ulcer therapy, study shows
BEIJING A research team led by Syed Rafatullah from Saudi Arabia validated the gastric anti-ulcer properties of the herb Rocket “Eruca sativa L.” (EER) on experimentally-induced gastric secretion and ulceration in albino rats. The study was published April 28 in the World Journal of Gastroenterology.
In recent years, Rocket “Eruca sativa L.” (EER), a member of the Brassicacae family, has gained greater importance as a salad vegetable and spice, especially among Middle Eastern populations and Europeans. It is believed that plants belonging to the Brassicacae family possess diversified medicinal and therapeutic properties including inhibition of tumorigenesis, anti-ulcer and hepatoprotective activities.
Although the introduction of proton-pump inhibitors to the classic anti-ulcer therapy has revolutionized treatment of peptic ulcers and other gastrointestinal disorders, there is still no complete cure for this disease, researchers noted. It has been shown that long term use of these drugs leads to various adverse and side effects. Relapses of the malady, ineffectiveness of different drug regimens and even resistance to drugs are emerging. Thus, there is an urgent requirement to identify more effective and safe anti-ulcer agents.
Researchers found that the ethanolic extract of EER significantly and dose-dependently reduced basal gastric acid secretion, titratable acidity and ruminal ulceration in lab rats. The authors concluded that EER extract possesses anti-ulcer activities against experimentally-induced gastric lesions.